Blood purification system for metabolic diseases

Abstract

The invention provides a blood purification system for metabolic diseases, which comprises a blood purification device, the blood purification device comprises a plurality of adsorption modules connected in parallel, the input ends of all the adsorption modules are connected with a first pipeline, and different adsorption modules comprise adsorbents for adsorbing different target substances in blood; the output ends of all the adsorption modules are connected with the second pipeline; wherein the first pipeline is used for conveying blood in a living body to the adsorption module, and the second pipeline is used for conveying the blood after target substances are adsorbed by the adsorption module back to the living body; for each adsorption module, the input end of the adsorption module is provided with a first flow adjusting valve, and the first flow adjusting valve is used for adjusting the blood flow speed, determined based on the preset duration, in the adsorption module. The blood purification system is applied to metabolic diseases, pathogenic factors of the metabolic diseases can be efficiently and accurately adsorbed, and the safety of blood purification is improved.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of blood purification, in particular to a blood purification system for metabolic diseases. BACKGROUND

[0002] Metabolic diseases are a class of diseases caused by abnormal metabolism of target substances in the body, such as familial hypercholesterolemia, drug-intolerant hyperlipidemia patients, diabetes combined with vascular lesions, and refractory hypertension. Traditional drug treatment has certain limitations in dealing with these diseases, for example, it is difficult to achieve good therapeutic effect for some drug-intolerant patients, and long-term drug treatment may bring a large metabolic burden to the liver and kidney and other organs. With the continuous development of medical technology, blood purification technology has been gradually applied to the treatment of metabolic diseases, but the existing related blood purification technology needs to be further improved in terms of targeting and safety. SUMMARY

[0003] The present application aims to solve the above-mentioned defects of the prior art, and provides a blood purification system for metabolic diseases, which can efficiently and accurately adsorb pathogenic factors of metabolic diseases when applied to metabolic diseases, and improves the safety of blood purification.

[0004] To solve the above problems, the present application provides a blood purification system for metabolic diseases, comprising:

[0005] a blood purification device, the blood purification device comprising a plurality of parallel adsorption modules, the input ends of all the adsorption modules being connected with a first pipeline, different adsorption modules comprising adsorbents for adsorbing different target substances in blood, the output ends of all the adsorption modules being connected with a second pipeline;

[0006] The first pipeline is used for transporting blood in a living body to the adsorption modules, and the second pipeline is used for transporting blood after adsorbing target substances by the adsorption modules back to the living body.

[0007] For each adsorption module, the input end of the adsorption module is provided with a first flow regulating valve, and the first flow regulating valve is used to adjust the blood flow rate in the adsorption module determined based on a preset time length.

[0008] Further comprising:

[0009] a processor for inputting physiological parameters of a living body into an adsorption amount prediction model, obtaining the adsorption amount of each target substance to be adsorbed output by the adsorption amount prediction model, and for each target substance, determining the target opening degree of the corresponding first flow regulating valve based on the preset time length according to the adsorption amount of the target substance to be adsorbed.

[0010] a controller configured to adjust the opening degree of each first flow regulating valve to a corresponding target opening degree respectively.

[0011] Further, a detector is arranged on the second pipeline to detect the real-time content of each target substance.

[0012] The processor is further configured to update the opening degree or opening duration of the corresponding first flow regulating valve according to the difference between the real-time content and the preset content of the corresponding target substance for each adsorption module.

[0013] Further, the updating of the opening degree or opening duration of the corresponding first flow regulating valve according to the difference between the real-time content and the preset content of the corresponding target substance for each adsorption module comprises:

[0014] If the difference between the real-time content and the preset content of the corresponding target substance is less than a preset threshold, the controller reduces the opening degree of the first flow regulating valve.

[0015] If the difference between the first content and the preset content of the corresponding target substance is greater than a preset threshold, the controller increases the opening degree of the first flow regulating valve or prolongs the opening duration of the first flow regulating valve until the difference between the real-time content and the preset content of the corresponding target substance is less than a preset threshold.

[0016] Further, the system further comprises a puncture blood drawing device, an arterial pot and a venous pot, the output end of the puncture blood drawing device and the input end of the arterial pot are connected through the first pipeline, the first output end of the arterial pot and the first input end of the blood purification device are connected through a third pipeline, the output end of the blood purification device and the first input end of the venous pot are connected through a fourth pipeline, and the output end of the venous pot is connected with the second pipeline.

[0017] For each adsorption module, the input end of the adsorption module is connected with the third pipeline through a first branch pipeline, the output end of the adsorption module is connected with the fourth pipeline through a second branch pipeline, and the first flow regulating valve is arranged on the first branch pipeline.

[0018] Further, the system further comprises a plasma separator, the input end of the plasma separator is connected with the second output end of the arterial pot through a fifth pipeline, the first output end of the plasma separator is connected with the second input end of the blood purification device through a sixth pipeline, the sixth pipeline is connected with each first branch pipeline, and the second output end of the plasma separator is connected with the second input end of the venous pot through a seventh pipeline.

[0019] Further, the third pipeline, the fifth pipeline and the sixth pipeline are provided with second flow regulating valves respectively, and the second flow regulating valves are used for regulating the blood flow or the plasma flow of the corresponding pipeline.

[0020] The output of the adsorption amount prediction model further includes a target adsorption mode, and the to-be-adsorbed amount of each target substance refers to the to-be-adsorbed amount of each target substance under the target adsorption mode; wherein the target adsorption mode is any one of a first adsorption mode, a second adsorption mode and a third adsorption mode, the first adsorption mode refers to adsorbing whole blood of a living body, the second adsorption mode refers to adsorbing plasma of a living body, and the third adsorption mode refers to simultaneously adsorbing whole blood and plasma of a living body.

[0021] The processor is further configured to determine a second target opening degree of each second flow regulating valve according to the target adsorption mode of the blood purification device.

[0022] The controller is further configured to adjust the opening degree of each second flow regulating valve to the corresponding second target opening degree determined by the processor.

[0023] Further, any two adjacent first branch pipes are provided with a second flow regulating valve.

[0024] Further, the puncture blood drawing device comprises a puncture needle and an artificial blood vessel, and the artificial blood vessel is connected to the puncture needle and the first pipeline, wherein the puncture needle comprises a needle body and a needle seat, a needle head is arranged at one end of the needle body away from the needle seat, the inside of the needle body is hollow, the needle seat is connected to the needle body and the artificial blood vessel, and the inner wall of the artificial blood vessel is coated with an anticoagulant coating.

[0025] Further, the blood purification device further comprises:

[0026] The anticoagulation device comprises an injection pipeline and a syringe, the input end of the injection pipeline is connected to the syringe, the syringe is used for injecting an anticoagulant into the injection pipeline, the output end of the injection pipeline is connected to the first pipeline, and the inner wall of the injection pipeline is coated with an anticoagulant coating.

[0027] The blood purification system for metabolic diseases provided by the present application can realize simultaneous adsorption of multiple target substances by arranging multiple parallel adsorption modules in the blood purification device, each of which is used for adsorbing different target substances, and each adsorption module can independently adsorb the target substance thereof, avoiding competition or interference between different adsorption modules; by arranging a first flow regulating valve at the input end of each adsorption module, the first flow regulating valve can adjust the blood flow rate in the adsorption module in real time, so as to timely adjust the adsorption efficiency of the corresponding adsorption module to the corresponding target substance, so that the blood purification device can flexibly adjust the adsorption efficiency of different target substances, so as to optimize the adsorption process, improve the total adsorption amount of the blood purification device, and ensure the accuracy and effectiveness of adsorption, avoiding the limitations of the existing blood purification system in single or fixed mode. In addition, by adjusting the blood flow rate in the adsorption module in real time, the side effects of the adsorption module can be reduced, and the release of the adsorbed target substance due to excessive saturation of the adsorbent in some adsorption modules can be avoided. The blood purification system provided by the present application can be applied to metabolic diseases, and the pathogenic factors in the blood can be adsorbed through extracorporeal circulation without the participation of drugs, avoiding the metabolism of drugs or the adverse effects on organs such as liver and kidney, and the blood purification system can also simultaneously adsorb multiple pathogenic factors according to individual differences, so as to realize precise adsorption of multiple pathogenic factors through single blood purification, avoiding multiple blood purification, improving the efficiency of blood purification, and flexibly adjusting the continuity and safety of blood purification, improving the targeting and safety of treatment.

[0028] In addition, the blood purification system provided by the present application can also detect the coagulation function related indexes by real-time collection of biological blood samples, dynamically regulate the infusion rate of the anticoagulant in the anticoagulation device according to the body weight and coagulation indexes of the organism, that is, the amount of anticoagulant, so as to ensure that the coagulation parameters of the organism remain within a safe range during the whole blood purification process, effectively solving the problem of forced treatment interruption due to coagulation in the current blood purification treatment. BRIEF DESCRIPTION OF DRAWINGS

[0029] Figure 1 The first structure schematic diagram of the blood purification system for metabolic diseases provided by the embodiment of the present application is shown in the figure;

[0030] Figure 2 The second structure schematic diagram of the blood purification system for metabolic diseases provided by the embodiment of the present application is shown in the figure;

[0031] Figure 3 The third structure schematic diagram of the blood purification system for metabolic diseases provided by the embodiment of the present application is shown in the figure. DETAILED DESCRIPTION

[0032] The technical solution of this application and how the technical solution of this application solves the above-mentioned technical problems are described in detail below with specific embodiments. These specific embodiments can be combined with each other, and the same or similar concepts or processes may not be described again in some embodiments. The embodiments of this application will be described below with reference to the accompanying drawings.

[0033] It should be noted that examples of embodiments of this application are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain this application, and should not be construed as limiting this application.

[0034] Those skilled in the art will understand that, unless explicitly stated otherwise, the singular forms “a,” “an,” and “the” used herein may also include the plural forms. It should be further understood that the term “comprising” as used in the specification of this application means the presence of features, integers, steps, operations, elements, and / or components, but does not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. It should be understood that when we say an element is “connected” or “coupled” to another element, it can be directly connected or coupled to the other element, or there may be intermediate elements. Furthermore, “connected” or “coupled” as used herein can include wireless connections or wireless coupling. The term “and / or” as used herein includes all or any units and all combinations of one or more associated listed items.

[0035] Combination Figures 1 to 3 As shown, the first aspect of this embodiment provides a blood purification system for metabolic diseases. The blood purification system includes: a blood purification device 10, which includes a plurality of adsorption modules connected in parallel. The input end of all adsorption modules is connected to a first pipeline 21. Different adsorption modules include adsorbents for adsorbing different target substances in the blood. The output end of all adsorption modules is connected to a second pipeline 22.

[0036] The first pipeline 21 is used to transport blood from the organism to the adsorption module, and the second pipeline 22 is used to return the blood after the target substance has been adsorbed by the adsorption module to the organism.

[0037] For each adsorption module, a first flow regulating valve 12 is provided at the input end of the adsorption module. The first flow regulating valve 12 is used to adjust the blood flow rate in the adsorption module based on a preset time.

[0038] The blood purification system for metabolic diseases provided in this embodiment incorporates multiple parallel adsorption modules, each designed to adsorb different target substances. This allows for the simultaneous adsorption of various target substances, and each module can independently adsorb its target substance, avoiding competition or interference between different modules. By installing a first flow regulating valve at the input of each adsorption module, the system can adjust the blood flow rate in real time, thereby adjusting the adsorption efficiency of the corresponding module for the target substance. This enables the blood purification device to flexibly adjust the adsorption efficiency for different target substances, optimizing the adsorption process, increasing the total adsorption capacity, and ensuring the accuracy and effectiveness of adsorption. This avoids the limitations of existing blood purification systems that struggle to adapt flexibly in single or fixed modes. Furthermore, by adjusting the blood flow rate in the adsorption modules in real time, side effects can be reduced, preventing oversaturation of the adsorbent in some modules and the release of adsorbed target substances. The blood purification system provided in this embodiment is applied to metabolic diseases. It can adsorb pathogenic factors in the blood through extracorporeal circulation without the need for drugs, thus avoiding drug metabolism or adverse effects on organs such as the liver and kidneys. Moreover, the blood purification system can adsorb multiple pathogenic factors simultaneously according to individual differences, so that multiple pathogenic factors can be accurately adsorbed in a single blood purification. This not only avoids multiple blood purifications and improves the efficiency of blood purification, but also allows for flexible adjustment to ensure the continuity and safety of blood purification, thereby improving the targeting and safety of treatment.

[0039] The adsorption module in this embodiment includes an adsorption chamber, the interior of which is filled with an adsorbent for adsorbing different target substances. Based on the above embodiment, as an optional implementation, the blood purification device 10 includes a first adsorption module 11A, a second adsorption module 11B, and a third adsorption module 11C. The first adsorption module 11A is filled with a first adsorbent for adsorbing lipids in the blood; the second adsorption module 11B is filled with a second adsorbent for adsorbing diabetic pathogenic factors in the blood, or a second adsorbent capable of simultaneously adsorbing diabetic pathogenic factors and blood regulatory factors in the blood; the third adsorption module 11C is filled with a third adsorbent for adsorbing inflammatory cytokines and oxidative stress products, or a third adsorbent capable of simultaneously adsorbing inflammatory cytokines, oxidative stress products, and nerve damage factors in the blood. The first, second, and third adsorbents can be existing adsorbents. For example, the first adsorbent can be polyacrylic acid resin grafted with polyacrylic acid; the second adsorbent can be a neutral macroporous adsorbent resin of divinyl styrene coated with collodion; and the third adsorbent can be a divinyl styrene adsorbent resin modified by PVA grafting. Of course, other types of adsorbents can also be used, as long as they can achieve the adsorption of the target substance.

[0040] Based on the above embodiments, as an optional implementation, the blood purification system further includes a processor and a controller;

[0041] The processor is used to input the physiological parameters of the organism into the adsorption amount prediction model, obtain the amount of each target substance to be adsorbed from the output of the adsorption amount prediction model, and for each target substance, determine the target opening degree of the first flow regulating valve 12 based on the amount of the target substance to be adsorbed based on the preset time.

[0042] The controller is used to adjust the opening degree of each of the first flow regulating valves 12 determined by the processor to the corresponding target opening degree.

[0043] The physiological parameters of the organism include weight, blood routine, biochemical indicators, and coagulation function. After these physiological parameters are input into the adsorption capacity prediction model, the model outputs the target substances to be adsorbed in the organism's blood and the amount of each target substance to be adsorbed. At this point, the adsorption module to be activated can be determined based on the target substances to be adsorbed, and the target opening degree of the corresponding first flow regulating valve 12 based on a preset time can be determined based on the amount of each target substance to be adsorbed. Subsequently, the controller adjusts the opening degree of each first flow regulating valve 12 determined by the processor to the corresponding target opening degree. Thus, by pre-determining the amount of each target substance to be adsorbed and determining the target opening degree of the corresponding first flow regulating valve 12 based on the amount of the target substance to be adsorbed, the flow rate of the organism's blood or plasma into each adsorption module can be adjusted within a suitable range, which is conducive to more precise adsorption of each target substance and improves the adsorption efficiency of the blood purification system.

[0044] It is understood that the embodiments of this application can also pre-train an adsorption amount prediction model. Specifically, the adsorption amount prediction model can be trained in the following way: First, collect a certain number of physiological parameters (including weight, blood routine, biochemical indicators, and coagulation function parameters) of biological samples, and determine the amount of each target substance to be adsorbed for each biological sample. Then, train the initial model based on the physiological parameters of each biological sample and the amount of each target substance to be adsorbed. The physiological parameters of the biological samples are used as training samples, and the amount of each target substance to be adsorbed for each biological sample is used as sample label, thereby obtaining the adsorption amount prediction model. The initial model can be a single neural network model or a combination of multiple neural network models. The neural network model can be a CNN (Convolutional Neural Network) model or an LSTM (Long Short-Term Memory) model.

[0045] In this embodiment, if the initial content of each target substance in the blood of an organism is Q1, and the preset content of each target substance is Qn, then the amount to be adsorbed for each target substance is the difference between the initial content and the preset content, i.e., the amount to be adsorbed = Q1 - Qn. The preset content of each target substance is the standard content for each target substance, which can be determined by those skilled in the art based on the standard for each target substance. Tables 1 to 3 below show some of the standard for target substances.

[0046] Based on the above embodiments, as an optional implementation, the preset time is 120 min to 240 min. Within this preset time range, both the effectiveness and safety of blood purification can be ensured. The target opening degree of each first flow regulating valve 12 can be the same or different. By adjusting the target opening degree of each first flow regulating valve 12, the flow rate of each first flow regulating valve 12 can be made from 0 to 250 L / min. When the flow rate of the first flow regulating valve 12 is 0, it indicates that the corresponding flow regulating valve 12 is in the closed state.

[0047] Based on the above embodiments, as an optional implementation, the second pipeline 22 is provided with a detector 221 for detecting the real-time content of each target substance;

[0048] The processor is also used to update the opening degree or opening duration of the corresponding first flow regulating valve 12 for each adsorption module based on the difference between the real-time content and the preset content of the corresponding target substance.

[0049] The detector 221 includes a detection branch and a detector. The detection branch is connected to the second pipeline 22. When it is necessary to detect the real-time content of each target substance, a trace amount of blood is aseptically taken out from the detection branch and returned to the body. The real-time content of each target substance in the blood is detected by a gas chromatograph or liquid chromatograph to determine the adsorption effect of each target substance. When it is not necessary to detect the real-time content of each target substance, the detection branch is closed to avoid contaminating the blood returned to the body.

[0050] Specifically, for each adsorption module, the opening degree or opening duration of the corresponding first flow regulating valve 12 is updated based on the difference between the real-time content and the preset content of the target substance, including:

[0051] If the difference between the real-time content of the corresponding target substance and the preset content is less than the preset threshold, the controller reduces the opening of the first flow regulating valve 12.

[0052] If the difference between the real-time content of the adsorbed target substance and the preset content is greater than the preset threshold, the controller increases the opening of the first flow regulating valve 12 or extends the opening time of the first flow regulating valve 12 until the difference between the real-time content of the adsorbed target substance and the preset content is less than the preset threshold.

[0053] In this embodiment, if the difference between the real-time content and the preset content of the adsorbed target substance is less than the preset threshold, it indicates that the adsorption rate of the target substance by the adsorption module has reached the expected level, and the opening of the first flow regulating valve 12 can be reduced. If the difference between the real-time content and the preset content of the adsorbed target substance is greater than the preset threshold, it indicates that the adsorption rate of the target substance by the adsorption module has not reached the expected level, and the opening of the first flow regulating valve 12 needs to be increased or the opening time of the first flow regulating valve 12 needs to be extended to allow more blood to flow into the adsorption module and improve the adsorption rate of the target substance by the adsorption module until the difference between the real-time content and the preset content of the adsorbed target substance is less than the preset threshold. Therefore, by setting a detector 221 on the second pipeline 22, the content of target substances in the blood can be detected in real time, and the opening degree of the corresponding first flow regulating valve 12 or the opening time of the first flow valve 12 can be dynamically adjusted in a timely manner according to the real-time content of the target substances, so as to further accurately and effectively adsorb each target substance, improve the adsorption efficiency of the blood purification system, and also improve the safety of the blood purification process, avoiding the risk of complications or safety risks caused by unreasonable target opening degree.

[0054] In this embodiment, the specific numerical range of the preset threshold is not further limited. Those skilled in the art can determine it based on the preset content of the target substance and the adsorption time of the blood by the corresponding adsorption module. Furthermore, when the difference between the real-time content and the preset content of the adsorbed target substance is less than the preset threshold, the real-time content is close to the preset content. At this time, the range of the difference between the real-time content and the preset content can be determined by those skilled in the art based on the actual situation. Generally speaking, the closer the real-time content is to the preset content, the better.

[0055] In this embodiment, when the difference between the real-time content and the preset content of the adsorbed target substance is greater than a preset threshold, the controller increases the opening of the first flow regulating valve 12 or extends the opening time of the first flow regulating valve 12 by a specific value that can be determined based on the actual amount to be adsorbed, the adsorption efficiency of the adsorption module, and the remaining time. The actual amount to be adsorbed is the difference between the real-time content Qt and the preset content Qn, i.e., actual amount to be adsorbed = Qt - Qn. The remaining time is the difference between the preset time and the adsorption time already taken. The adsorption efficiency of the adsorption module can be determined based on the adsorption efficiency of the adsorbent in the adsorption module. When the difference between the real-time content and the preset content of the adsorbed target substance is less than a preset threshold, the controller decreases the opening of the first flow regulating valve 12 by a specific value that can be determined based on the blood flow rate (or plasma flow rate) flowing into the blood purification device 10 and the opening of other first flow regulating valves 12. It can be understood that the sum of the blood flow rates (or plasma flow rates) in each adsorption module is equal to the blood flow rate (or plasma flow rate) delivered to the blood purification device 10. Of course, when the difference between the real-time content of the corresponding target substance adsorbed and the preset content is less than the preset threshold, the controller can also close the first flow regulating valve 12.

[0056] In order to enable blood purification treatment for different metabolic diseases and improve the applicability of the blood purification system, the blood purification device 10 in this embodiment can perform whole blood adsorption, plasma adsorption, or both.

[0057] Specifically, in combination Figures 1 to 3 As shown, the blood purification system in this embodiment also includes a puncture and blood extraction device 30, an arterial chamber 40, and a venous chamber 50. The output end of the puncture and blood extraction device 30 and the input end of the arterial chamber 40 are connected through a first pipeline 21. The first output end of the arterial chamber 40 and the first input end of the blood purification device 10 are connected through a third pipeline 23. The output end of the blood purification device 10 and the first input end of the venous chamber 50 are connected through a fourth pipeline 24. The output end of the venous chamber 50 is connected to a second pipeline 22.

[0058] For each adsorption module, the input end of the adsorption module is connected to the third pipeline 23 through the first branch pipe 13, and the output end of the adsorption module is connected to the fourth pipeline 24 through the second branch pipe 14. The first flow regulating valve 12 is installed on the first branch pipe 13.

[0059] The blood purification system with the above structure can adsorb whole blood from an organism. The puncture blood extraction device 30 draws blood from the organism and delivers it to the arterial chamber 40 through the first pipeline 21. After the air bubbles are removed in the arterial chamber 40, the blood is delivered to the blood purification device 10 through the third pipeline 23. The blood in the third pipeline 23 is diverted to each adsorption module through each first branch pipe 13. After the target substance is adsorbed by the adsorption module, the blood is delivered to the fourth pipeline 24 through each second branch pipe 14. The fourth pipeline 24 delivers the blood after the target substance is adsorbed to the venous chamber 50. After the air bubbles are removed in the venous chamber 50, the blood is returned to the organism through the second pipeline 22. In this embodiment, the first pipeline 21 and each of the first branch pipes 13 are connected by the arterial pot 40 and the third pipeline 23. This can intercept air bubbles and blood clots in the first pipeline 21. A flow meter can be installed on the arterial pot 40 to monitor the blood flow rate delivered to the third pipeline 23, ensuring the stability of the blood flow rate delivered to the third pipeline 23. This ensures the stability of the blood flow rate delivered to the corresponding adsorption module by each first branch pipe 13, so as to more accurately adjust the adsorption efficiency of the corresponding adsorption module for the target substance.

[0060] Based on the above embodiments, as an optional implementation method, combined with Figure 2 and Figure 3 As shown, the blood purification system also includes a plasma separator 60. The input end of the plasma separator 60 is connected to the second output end of the arterial chamber 40 via a fifth pipe 25. The first output end of the plasma separator 60 is connected to the second input end of the blood purification device 10 via a sixth pipe 26. The sixth pipe 26 is connected to each of the first branch pipes 13. The second output end of the plasma separator 60 is connected to the second input end of the venous chamber 50 via a seventh pipe 27.

[0061] The blood purification system with the above structure can selectively adsorb plasma from a living organism. The puncture and blood extraction device 30 draws blood from the organism and delivers it to the arterial chamber 40 through the first pipeline 21. After the air bubbles are removed in the arterial chamber 40, the blood is delivered to the plasma separator 60 through the fifth pipeline 25. The plasma separator 60 separates the formed elements (blood cells and platelets) of the plasma and blood. The plasma is delivered to the blood purification device 10 through the sixth pipeline 26 and is diverted to the adsorption modules through the first branch pipes 13. After the adsorption modules adsorb the target substances, the plasma is delivered to the fourth pipeline 24 through the second branch pipes 14. The fourth pipeline 24 delivers the plasma with the adsorbed target substances to the venous chamber 50. After the air bubbles are removed in the venous chamber 50, the plasma is returned to the organism through the second pipeline 22. The formed elements of the blood are delivered to the venous chamber 50 through the seventh pipeline 27. After the air bubbles are removed in the venous chamber 50, the formed elements of the blood are returned to the organism through the second pipeline 22. In this embodiment, the fifth conduit 25 connects the arterial chamber 40 and the plasma separator 60, intercepting air bubbles and blood clots in the first conduit 21. The sixth conduit 26 connects the plasma separator 60 and each of the first branch pipes 13. After plasma separation, it can be directly transported to each adsorption module via the sixth conduit 26 and each of the first branch pipes 13, avoiding delays in plasma transport and shortening the transport time. This not only facilitates timely adsorption of target substances by each adsorption module but also avoids the risk of coagulation caused by prolonged plasma transport. Furthermore, by installing a flow meter on the sixth conduit 26, the stability of the blood flow rate delivered from each first branch pipe 13 to the corresponding adsorption module can be ensured, allowing for more precise adjustment of the adsorption efficiency of the respective adsorption module for the target substance.

[0062] In this embodiment, by connecting the input end of the blood purification device 10 to the output end of the arterial chamber 40 or the output end of the plasma separator 60, the blood purification device 10 can be used for both whole blood adsorption and plasma adsorption. Furthermore, when the first input end of the blood purification device 10 is connected to the first output end of the arterial chamber 40, the second input end of the blood purification device 10 is also connected to the first output end of the plasma separator 60, allowing the blood purification device to simultaneously perform whole blood adsorption and plasma adsorption. Therefore, this blood purification system can be used for different blood purification modes and can be used to treat different metabolic diseases, thus improving the applicability of the blood purification system.

[0063] Based on the above embodiments, as an optional implementation, a second flow regulating valve 28 is provided on the third pipeline 23, the fifth pipeline 25 and the sixth pipeline 26. The second flow regulating valve 28 is used to regulate the blood flow or plasma flow of the corresponding pipeline.

[0064] The output of the adsorption capacity prediction model also includes the target adsorption mode. The amount to be adsorbed for each target substance refers to the amount to be adsorbed for each target substance under the target adsorption mode. The target adsorption mode is any one of the first adsorption mode, the second adsorption mode and the third adsorption mode. The first adsorption mode refers to the blood purification device 10 adsorbing the whole blood of the organism. The second adsorption mode refers to the blood purification device 10 adsorbing the plasma of the organism. The third adsorption mode refers to the blood purification device 10 adsorbing both the whole blood and plasma of the organism at the same time.

[0065] The processor is also used to: determine the second target opening degree of each second flow regulating valve 28 according to the target adsorption mode of the blood purification device 10;

[0066] The controller is also used to adjust the opening degree of each of the second flow control valves 28 determined by the processor to the corresponding second target opening degree.

[0067] Based on the adsorption mode of the blood purification device 10 output by the adsorption prediction model, those skilled in the art can determine whether the blood purification system adsorbs whole blood, plasma, or both at the same time on the organism. The controller then determines the second target opening degree of each second flow regulating valve 28 according to the corresponding blood purification mode. The controller adjusts the opening degree of each second flow regulating valve 28 determined by the processor to the corresponding second target opening degree so that the blood purification system performs the corresponding blood purification mode on the organism.

[0068] Specifically, when adsorbing whole blood from a living organism, the second target opening of the second flow regulating valve 28 on the fifth and sixth pipelines 25 and 26 is zero, meaning the second flow regulating valve 28 on the fifth and sixth pipelines 25 and 26 is closed, while the second flow regulating valve 28 on the third pipeline 23 is open. At this time, there is no blood flow in the fifth and sixth pipelines 25 and 26, and the blood in the arterial chamber 40 is transported to the blood purification device 10 for adsorption through the third pipeline 23. When adsorbing plasma from a living organism, the second flow regulating valve 28 on the fifth and sixth pipelines 25 and 26 is open, while the second target opening of the second flow regulating valve 28 on the third pipeline 23 is zero, meaning the second flow regulating valve 28 on the third pipeline 23 is closed. At this time, there is no plasma flow in the third pipeline 23, and the blood in the arterial chamber 40 is transported sequentially to the blood purification device 10 for adsorption through the fifth and sixth pipelines 25 and 26. When adsorbing whole blood and plasma from a living organism simultaneously, the second flow regulating valves 28 on the third pipeline 23, the fifth pipeline 25, and the sixth pipeline 26 are all opened. By adjusting the second target opening of each second flow regulating valve 28, the blood flow or plasma flow of the corresponding pipeline is adjusted so that the blood flow and plasma flow are within a suitable range, thereby improving the adsorption efficiency of the blood purification device 10.

[0069] It is understood that the embodiments of this application can also pre-train an adsorption amount prediction model. Specifically, the adsorption amount prediction model can be trained in the following way: First, collect a certain number of physiological parameters (including weight, blood routine, biochemical indicators, and coagulation function parameters) of biological samples, and determine the target adsorption mode of each biological sample and the amount of each target substance to be adsorbed under the corresponding target adsorption mode. Then, train the initial model based on the physiological parameters of each biological sample, the target adsorption mode of each biological sample, and the amount of each target substance to be adsorbed under the corresponding target adsorption mode. The physiological parameters of the biological samples are used as training samples, and the target adsorption mode of the biological samples and the amount of each target substance to be adsorbed under the corresponding target adsorption mode are used as sample labels, thereby obtaining the adsorption amount prediction model. The initial model can be a single neural network model or a combination of multiple neural network models. The neural network model can be a CNN (Convolutional Neural Network) model or an LSTM (Long Short-Term Memory) model.

[0070] Based on the above embodiments, as an optional implementation, a second flow regulating valve 28 is provided between any two adjacent first branch pipes 13. Through the second flow regulating valve 28 between any two adjacent first branch pipes 13, blood can be delivered to some adsorption modules for whole blood adsorption, while plasma can be delivered to other adsorption modules for plasma adsorption. This allows the blood purification device 10 to simultaneously perform whole blood adsorption and plasma adsorption, avoiding confusion between the two processes and facilitating targeted adsorption of the target substance by the adsorption modules, thereby improving the adsorption efficiency of the blood purification device 10. For example, a second flow regulating valve 28 is provided between the first branch pipe 13 connected to the first adsorption module 11A and the first branch pipe 13 connected to the second adsorption module 11B, and between the first branch pipe 13 connected to the second adsorption module 11B and the first branch pipe 13 connected to the third adsorption module 11C.

[0071] Based on the above embodiments, as an optional implementation, the sixth pipeline 26 is provided with a plasma pump 261 and a plasma reservoir 262. The plasma pump 261 is used to drive the plasma flow in the sixth pipeline 26, so that the plasma flow rate in the sixth pipeline 26 can be kept stable, ensuring the smooth and safe flow of plasma during the blood purification process; the plasma reservoir 262 is used to remove air bubbles from the plasma.

[0072] Based on the above embodiments, as an optional implementation, a blood pump 211 is provided on the first pipeline 21. The blood pump 211 is used to drive the blood flow in the first pipeline 21, so that the blood flow rate in the first pipeline 21 can be kept stable, ensuring the smooth and safe flow of blood during the blood purification process.

[0073] Based on the above embodiments, as an optional implementation, the puncture and blood-drawing device 30 includes a puncture needle and an artificial blood vessel. The artificial blood vessel connects the puncture needle and the first conduit 21. The puncture needle includes an integrally formed needle body and a needle hub. A needle tip is provided at the end of the needle body opposite to the needle hub. The needle tip has a sharp point to pierce the organism. The needle body is hollow inside. The needle hub connects the needle body and the artificial blood vessel, so that blood in the organism can be transported to the first conduit 21 through the artificial blood vessel. In this embodiment, the needle tip can be a blunt needle to reduce pain and tissue tearing caused by puncture. The surface of the needle tip is coated with an anesthetic drug such as lidocaine to provide microanesthesia to the organism and reduce the organism's pain. The diameter of the needle body is 16Ga to 20Ga (Ga is an abbreviation for Gauge; the larger the Gauge value, the thinner the needle body) to reduce the damage from repeated punctures. The artificial blood vessel is made of ePTFE (expanded polytetrafluoroethylene). ePTFE is non-toxic to the human body and has good biocompatibility, making it highly safe for use in medical devices and human implants. When performing puncture needle insertion, ultrasound guidance can be used to puncture superficial veins of the upper limb (such as the median cubital vein, cephalic vein, and basilic vein) to accurately locate the blood vessels and avoid damage caused by repeated punctures.

[0074] Based on the above embodiments, as an optional implementation, the blood purification system further includes an anticoagulant device 70. The anticoagulant device 70 includes an injection tubing 71 and a syringe 72. The input end of the injection tubing 71 is connected to the syringe 72, which injects an anticoagulant into the injection tubing 71. The output end of the injection tubing 71 is connected to the first tubing 21. Thus, by connecting the anticoagulant device 70 to the first tubing 21, blood coagulation is prevented during blood purification. In this embodiment, the syringe 72 can be a high-precision injection pump (accuracy 0.1 mL / min). The high-precision injection pump is filled with an anticoagulant, which may include heparin (unfractionated heparin / low molecular weight heparin), sodium citrate, or novel anticoagulants (such as argatroban). Before blood purification, those skilled in the art can adjust the dosage of the anticoagulant according to the organism's weight and coagulation indicators to ensure that the blood coagulation capacity remains within a safe range during blood purification. Coagulation parameters include INR (International Normalized Ratio) and APTT (Activated Partial Thromboplastin Time). INR is a key indicator for assessing whether anticoagulation therapy is achieving optimal results. The normal range for INR is typically between 0.8 and 1.5. A low INR indicates insufficient anticoagulation, increasing the risk of thrombosis, in which case the anticoagulation system will increase the dosage of anticoagulants. Conversely, a high INR indicates excessive anticoagulation, potentially increasing the risk of bleeding, in which case the anticoagulation system should reduce the dosage of anticoagulants. APTT is the most commonly used coagulation function test in clinical practice and can be used to determine whether an individual's coagulation function is normal. The normal reference range for APTT is usually 25 to 37 seconds. When APTT is higher than the normal range, it indicates that there are more anticoagulants in the blood, which may pose a risk of bleeding. In this case, the anticoagulant system should reduce the dosage of anticoagulants. When APTT is lower than the normal range, it indicates that there are fewer anticoagulants in the blood, which may pose a risk of coagulation. In this case, the anticoagulant system will increase the dosage of anticoagulants.

[0075] This embodiment can detect coagulation function-related indicators by collecting blood samples from organisms in real time. Based on the organism's weight and coagulation indicators, the infusion rate and dosage of anticoagulant in the anticoagulant device 70 can be dynamically adjusted to ensure that the organism's coagulation parameters remain within a safe range throughout the entire blood purification process. This effectively solves the drawback of current blood purification treatments where treatment is forced to be stopped midway after coagulation occurs.

[0076] Based on the above embodiments, as an optional implementation, the inner wall of the artificial blood vessel is coated with an anticoagulant coating, and / or the inner wall of the injection tubing 71 is coated with an anticoagulant coating, which may be heparin. Thus, by applying anticoagulant coatings to the inner walls of the artificial blood vessel and the injection tubing 71, thrombus formation can be reduced, and the risk of coagulation can be lowered. Preferably, both the inner wall of the artificial blood vessel and the inner wall of the injection tubing 71 are coated with an anticoagulant coating.

[0077] The processor in this embodiment can be a CPU (Central Processing Unit), a general-purpose processor, a DSP (Digital Signal Processor), an ASIC (Application Specific Integrated Circuit), an FPGA (Field Programmable Gate Array), or other programmable logic devices, transistor logic devices, hardware components, or any combination thereof. It can implement or execute various exemplary logic blocks, modules, and circuits described in conjunction with the disclosure of this application. The processor can also be a combination that implements computational functions, such as a combination of one or more microprocessors, a combination of a DSP and a microprocessor, etc. To further describe the present invention in detail, specific embodiments will be used to further illustrate the invention below. Unless otherwise specified, the experimental methods used in the embodiments of the present invention are conventional methods; unless otherwise specified, the materials and reagents used in the embodiments of the present invention are commercially available.

[0078] Example 1

[0079] Combination Figure 1 As shown, in this embodiment, a blood purification system for metabolic diseases is applied to blood purification in patients with hyperlipidemia and diabetes, specifically including:

[0080] After the organism's physiological parameters (including weight, blood routine, biochemical indicators, and coagulation function, etc.) are input into the processor, the first adsorption mode (i.e., the blood purification device 10 adsorbs the organism's whole blood) and the amount of each target substance to be adsorbed under the first adsorption mode are obtained through the adsorption capacity prediction model. At this time, the target substances include lipids, diabetes pathogenic factors, inflammatory cytokines, and oxidative stress products. Based on the first adsorption mode and the amount of each target substance to be adsorbed under the first adsorption mode, the following can be determined:

[0081] After 2 hours of adsorption in the first adsorption mode, the three adsorption modules in the blood purification device 10 are connected in parallel, and the fifth pipeline 25 is closed (because in the first adsorption mode, the second flow regulating valve 28 on the sixth pipeline 26 is always closed, therefore...).Figure 1 The sixth pipeline 26 is omitted. The second flow regulating valve 28 on the third pipeline 23 is opened. The first flow regulating valves 12 on each first branch pipe 13 are all opened. The second flow regulating valves 28 between the first branch pipe 13 connected to the first adsorption module 11A and the first branch pipe 13 connected to the second adsorption module 11B are opened. The second flow regulating valves 28 between the first branch pipe 13 connected to the second adsorption module 11B and the first branch pipe 13 connected to the third adsorption module 11C are opened. The blood in the third pipeline 23 is divided into three streams and flows into the first adsorption module 11A, the second adsorption module 11B and the third adsorption module 11C for adsorption. The first adsorption module 11A is filled with a first adsorbent that adsorbs lipids in the blood. The second adsorption module 11B is filled with a second adsorbent that adsorbs diabetes pathogenic factors in the blood. The third adsorption module 11C is filled with a third adsorbent that adsorbs inflammatory cytokines and oxidative stress products.

[0082] The blood pump 211 has a flow rate of 150 mL / min. The first target opening of each first flow regulating valve 12 is the same, so that the blood flow rate in each first branch pipe 13 is the same. That is, the blood flow rate VA flowing into the first adsorption module 11A is 50 mL / min, the blood flow rate VB flowing into the second adsorption module 11B is 50 mL / min, and the blood flow rate VC flowing into the third adsorption module 11C is 50 mL / min. In addition, during the blood purification process, the anticoagulant device adopts the systemic heparinization method. The initial heparin dose is 0.5 mg to 1.0 mg / kg, and the supplementary heparin dose is 10 mg / h to 20 mg / h. The supplementary dose is stopped half an hour before the end of perfusion.

[0083] One hour after blood purification, the real-time content of each target substance in the blood after adsorption by the blood purification device 10 is detected by detector 221. After detection, it was found that the content of lipids and inflammatory cytokines in the blood of the organism was close to the standard (as shown in Table 1), but the concentration of diabetic pathogenic factors was still much higher than the normal concentration, indicating that the adsorption rate of diabetic pathogenic factors by the second adsorption module 11B did not reach the expected level. At this time, it is necessary to calculate the actual amount of diabetic pathogenic factors to be adsorbed based on the real-time content of diabetic pathogenic factors and increase the value of the blood flow rate VB flowing into the second adsorption module 11B. For example: Based on the organism's weight, the actual amount of diabetic pathogenic factors to be adsorbed in the organism's blood, Qd, is calculated to be 10 mmol. The adsorption efficiency K of the second adsorption module 11B is 0.12 mmol / min, and the remaining blood purification time t is 1 hour (60 minutes). Therefore, the adsorption efficiency needs to be increased to K1, where K1 = Qd / t = 10 / 60 = 0.167 mmol / min. According to the conversion, the blood flow rate VB should be proportionally increased to (K1 / K) × VB = (0.167 / 0.12) × 50 = 70 mL / min. Simultaneously, to maintain a total blood flow rate of 150 mL / min, the blood flow rates VA and VC are adjusted to 40 mL / min each. Subsequently, by adjusting the opening of the corresponding first flow regulating valve 12, the blood flow rates of VA and VC are adjusted to 40 mL / min, and the blood flow rate of VB is adjusted to 70 mL / min. After continuing blood purification for a period of time, the real-time content of each target substance in the blood after being adsorbed by the blood purification device 10 is detected again by detector 221, and the above steps are repeated until the content of each target substance reaches the standard. Blood purification is then stopped, each first flow regulating valve 12 and second flow regulating valve 28 is closed, and the first pipeline 21 and second pipeline 22 connected to the organism are disconnected.

[0084] Table 1

[0085]

[0086]

[0087] Example 2

[0088] Combination Figure 2 As shown, in this embodiment, a blood purification system for metabolic diseases is applied to metabolic syndrome for blood purification, specifically including:

[0089] After the organism's physiological parameters (including weight, blood routine, biochemical indicators, and coagulation function, etc.) are input into the processor, the second adsorption mode (i.e., the blood purification device 10 adsorbs the organism's plasma) and the amount of each target substance to be adsorbed under the second adsorption mode are obtained through the adsorption capacity prediction model. At this time, the target substances include lipids, diabetes pathogenic factors, blood pressure regulating factors, inflammatory cytokines, and oxidative stress products. Based on the second adsorption mode and the amount of each target substance to be adsorbed under the second adsorption mode, the following can be determined:

[0090] In the second adsorption mode, adsorption is carried out for 1.5 hours. The three adsorption modules in the blood purification device 10 are connected in parallel, and the second flow regulating valve 28 on the fifth pipeline 25 is opened (because in the second adsorption mode, the second flow regulating valve 28 on the third pipeline 23 is always closed, therefore...). Figure 2 The third pipeline 23 is omitted. The second flow regulating valve 28 on the sixth pipeline 26 is opened, and the first flow regulating valves 12 on each of the first branch pipes 13 are opened. The second flow regulating valves 28 between the first branch pipe 13 connected to the first adsorption module 11A and the first branch pipe 13 connected to the second adsorption module 11B are also opened. The second flow regulating valve 28 between the first branch pipe 13 connected to the second adsorption module 11B and the first branch pipe 13 connected to the third adsorption module 11C is also opened. Blood in the arterial chamber 40 enters the blood separator 60. The plasma separated by the plasma separator 60 is transported to the blood purification device 10 through the sixth pipeline 26 and is divided into three streams that flow into the first adsorption module 11A, the second adsorption module 11B, and the third adsorption module 11C for adsorption. The first adsorption module 11A is filled with a first adsorbent that adsorbs lipids in the blood, the second adsorption module 11B is filled with a second adsorbent that adsorbs factors causing diabetes and blood pressure regulating factors in the blood, and the third adsorption module 11C is filled with a third adsorbent that adsorbs inflammatory cytokines and oxidative stress products.

[0091] After separation by plasma separator 60, the total plasma flow rate in the sixth pipeline 26 is 50 mL / min. According to the amount of each target substance to be adsorbed, the first target opening of each first flow regulating valve 12 is adjusted so that the blood flow rate VA flowing into the first adsorption module 11A is 10 mL / min, the blood flow rate VB flowing into the second adsorption module 11B is 10 mL / min, and the blood flow rate VC flowing into the third adsorption module 11C is 30 mL / min. In addition, during the blood purification process, the anticoagulant device adopts the systemic heparinization method. The initial heparin dose is 0.5 mg to 1.0 mg / kg, and the supplementary heparin dose is 10 mg / h to 20 mg / h. The supplementary dose is stopped half an hour before the end of perfusion.

[0092] One hour after blood purification, the real-time content of various target substances in the blood after adsorption by the blood purification device 10 was detected by detector 221. After detection, it was found that the content of substances such as diabetes pathogenic factors, blood pressure regulating factors and inflammatory cytokines in the blood of the organism was close to the standard (as shown in Table 2). However, the concentration of lipids was still much higher than the normal concentration, indicating that the adsorption rate of lipids by the first adsorption module 11A did not reach the expected level. At this time, it is necessary to calculate the actual amount of lipids to be adsorbed based on the real-time content of lipids and extend the blood purification time. For example: Based on the organism's weight, the actual amount of lipids to be adsorbed in the organism's blood, Qd, is calculated to be 50 mmol. The adsorption efficiency K of the first adsorption module 11A is 1.2 mmol / min, and the remaining blood purification time t is 0.5 h (i.e., 30 min). If blood purification continues at the current adsorption efficiency, the remaining blood purification time until the lipids reach the standard is T = Qd / K = 50 / 1.2 = 41.7 min. Since the remaining blood purification time t is 30 min, the readjusted remaining blood purification time is 41.7 min. Therefore, the blood purification time is extended by 11.7 min. Subsequently, the blood purification time is extended to 41.7 min. After continuing blood purification for a period of time, the real-time content of each target substance in the blood after being adsorbed by the blood purification device 10 is detected again by detector 221, and the above steps are repeated until the content of each target substance reaches the standard. Blood purification is then stopped, each first flow regulating valve 12 and second flow regulating valve 28 is closed, and the first pipeline 21 and second pipeline 22 connected to the organism are disconnected.

[0093] Table 2

[0094]

[0095]

[0096] Example 3

[0097] Combination Figure 3 As shown, in this embodiment, a blood purification system for metabolic diseases is applied to blood purification in metabolic syndrome complicated with acute ischemic stroke, specifically including:

[0098] After the organism's physiological parameters (including weight, complete blood count, biochemical indicators, and coagulation function) are input into the processor, the third adsorption mode (i.e., the blood purification device 10 simultaneously adsorbs whole blood and plasma) and the amount of each target substance to be adsorbed in the third adsorption mode are obtained through the adsorption capacity prediction model. At this time, the target substances include lipids, diabetes pathogenic factors, inflammatory cytokines, oxidative stress products, and nerve damage factors. Based on the third adsorption mode and the amount of each target substance to be adsorbed in the third adsorption mode, the following can be determined:

[0099] After 2 hours of adsorption in the third adsorption mode, the three adsorption modules in the blood purification device 10 are connected in parallel. The second flow regulating valves 28 on the third pipeline 23, the fifth pipeline 25, and the sixth pipeline 26 are opened, and the first flow regulating valves 12 on each of the first branch pipes 13 are also opened. The second flow regulating valve 28 between the first branch pipe 13 connected to the first adsorption module 11A and the first branch pipe 13 connected to the second adsorption module 11B is closed, while the second flow regulating valve 28 between the first branch pipe 13 connected to the second adsorption module 11B and the first branch pipe 13 connected to the third adsorption module 11C is opened. A portion of the blood in the arterial chamber 40 enters the blood separator 60 and is separated from the plasma. The plasma separated by the device 60 is transported to the blood purification device 10 through the sixth pipeline 26 and is divided into two streams that flow into the second adsorption module 11B and the third adsorption module 11C for adsorption. Another part of the blood in the arterial chamber 40 enters the blood purification device 10 through the third pipeline 23 and enters the second adsorption module 11A through the first branch pipe 13 for adsorption. The first adsorption module 11A is filled with a first adsorbent that adsorbs lipids in the blood, the second adsorption module 11B is filled with a second adsorbent that adsorbs diabetes pathogenic factors in the blood, and the third adsorption module 11C is filled with a third adsorbent that adsorbs inflammatory cytokines, oxidative stress products, and nerve damage factors.

[0100] The total blood flow rate in the third pipeline 23 is 50 mL / min. Since all the blood in the third pipeline 23 is delivered to the first adsorption module 11A, the blood flow rate VA flowing into the first adsorption module 11A is 50 mL / min. The total plasma flow rate in the sixth pipeline 26 is 30 mL / min. Based on the amount of each target substance to be adsorbed, the first target opening of each first flow regulating valve 12 is adjusted to make the blood flow rate VB flowing into the second adsorption module 11B 20 mL / min and the blood flow rate VC flowing into the third adsorption module 11C 10 mL / min. Furthermore, during the blood purification process, the anticoagulant device uses a systemic heparinization method. The initial heparin dose is 0.5 mg to 1.0 mg / kg, with subsequent heparin doses of 10 mg / h to 20 mg / h. Supplementation is stopped half an hour before the end of perfusion.

[0101] One hour after blood purification, the real-time content of each target substance in the blood after adsorption by the blood purification device 10 was detected by detector 221. After detection, it was found that the content of lipids and diabetes pathogenic factors in the blood of the organism was close to the standard (as shown in Table 3). However, the adsorption rate of nerve damage factors, inflammatory cytokines and oxidative stress products was lower than expected. This indicates that the adsorption rate of nerve damage factors, inflammatory cytokines and oxidative stress products by the third adsorption module 11C did not reach the expected level. At this time, it is necessary to calculate the actual amount of nerve damage factors, inflammatory cytokines and oxidative stress products to be adsorbed based on the real-time content of nerve damage factors, inflammatory cytokines and oxidative stress products, and increase the value of the blood flow rate VC flowing into the third adsorption module 11C. For example: Based on the organism's weight, the actual amount of neurodegrading factors, inflammatory cytokines, and oxidative stress products to be adsorbed in the organism's blood, Qd, is 80 mmol. The adsorption efficiency K of the third adsorption module 11C is 0.8 mmol / min, and the remaining blood purification time t is 1 hour (60 minutes). At this time, the adsorption efficiency needs to be increased to K1, K1 = Qd / t = 80 / 60 = 1.33 mmol / min. According to the conversion, the blood flow rate VC should be increased proportionally to (K1 / K) × VC = (1.33 / 0.8) × 10 = 16.7 mL / min. At the same time, in order to ensure that the total blood flow rate of the third tube 23 and the total plasma flow rate of the sixth tube 26 remain unchanged, the plasma flow rate of VB is adjusted to 30 - 16.7 = 13.3 mL / min. Subsequently, by adjusting the opening of the corresponding first flow regulating valve 12, the blood flow rate of VB is adjusted to 13.3 mL / min, and the blood flow rate of VC is adjusted to 16.7 mL / min. After continuing blood purification for a period of time, the real-time content of each target substance in the blood after adsorption by the blood purification device 10 is detected again by detector 221, and the above steps are repeated until the content of each target substance reaches the standard. Blood purification is then stopped, the first flow regulating valve 12 and the second flow regulating valve 28 are closed, and the first tubing 21 and the second tubing 22 connected to the organism are disconnected.

[0102] Table 3

[0103]

[0104] While the disclosure is as stated above, its scope of protection is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of this disclosure, and all such changes and modifications will fall within the protection scope of this invention.

Claims

1. A blood purification system for metabolic diseases, characterized in that, include: A blood purification device, comprising multiple adsorption modules connected in parallel, the input end of all adsorption modules being connected to a first pipeline, different adsorption modules comprising adsorbents for adsorbing different target substances in the blood, and the output end of all adsorption modules being connected to a second pipeline. The first pipeline is used to transport blood from the organism to the adsorption module, and the second pipeline is used to return the blood after the target substance has been adsorbed by the adsorption module back to the organism. For each of the adsorption modules, a first flow regulating valve is provided at the input end of the adsorption module. The first flow regulating valve is used to adjust the blood flow rate in the adsorption module based on a preset time.

2. The blood purification system according to claim 1, characterized in that, Also includes: The processor is used to input the physiological parameters of the organism into the adsorption amount prediction model, obtain the amount of each target substance to be adsorbed output by the adsorption amount prediction model, and for each target substance, determine the target opening degree of the corresponding first flow regulating valve based on the amount of the target substance to be adsorbed based on a preset time. The controller is used to adjust the opening degree of each of the first flow regulating valves determined by the processor to the corresponding target opening degree.

3. The blood purification system according to claim 2, characterized in that, The second pipeline is equipped with a detector for detecting the real-time content of each target substance; The processor is also used to: for each adsorption module, update the opening degree or opening duration of the corresponding first flow regulating valve according to the difference between the real-time content and the preset content of the corresponding target substance.

4. The blood purification system according to claim 3, characterized in that, For each adsorption module, the opening degree or opening duration of the corresponding first flow regulating valve is updated based on the difference between the real-time content and the preset content of the target substance, including: If the difference between the real-time content of the adsorbed target substance and the preset content is less than the preset threshold, the controller reduces the opening of the first flow regulating valve. If the difference between the first content and the preset content of the adsorbed target substance is greater than the preset threshold, the controller increases the opening of the first flow regulating valve or extends the opening time of the first flow regulating valve until the difference between the real-time content and the preset content of the adsorbed target substance is less than the preset threshold.

5. The blood purification system according to claim 2, characterized in that, It also includes a puncture and blood-drawing device, an arterial chamber, and a venous chamber. The output end of the puncture and blood-drawing device and the input end of the arterial chamber are connected through the first pipeline. The first output end of the arterial chamber and the first input end of the blood purification device are connected through the third pipeline. The output end of the blood purification device and the first input end of the venous chamber are connected through the fourth pipeline. The output end of the venous chamber is connected to the second pipeline. For each of the adsorption modules, the input end of the adsorption module is connected to the third pipeline through a first branch pipe, and the output end of the adsorption module is connected to the fourth pipeline through a second branch pipe. The first flow regulating valve is installed on the first branch pipe.

6. The blood purification system according to claim 5, characterized in that, It also includes a plasma separator, the input end of which is connected to the second output end of the arterial chamber via a fifth pipeline, the first output end of which is connected to the second input end of the blood purification device via a sixth pipeline, the sixth pipeline being connected to each of the first branch pipes, and the second output end of the plasma separator being connected to the second input end of the venous chamber via a seventh pipeline.

7. The blood purification system according to claim 6, characterized in that, The third, fifth, and sixth pipelines are each equipped with a second flow regulating valve, which is used to regulate the blood flow or plasma flow of the corresponding pipeline. The output of the adsorption capacity prediction model also includes a target adsorption mode, wherein the amount to be adsorbed for each target substance refers to the amount to be adsorbed for each target substance under the target adsorption mode; wherein the target adsorption mode is any one of the first adsorption mode, the second adsorption mode and the third adsorption mode, wherein the first adsorption mode refers to adsorbing whole blood of an organism, the second adsorption mode refers to adsorbing plasma of an organism, and the third adsorption mode refers to adsorbing both whole blood and plasma of an organism simultaneously. The processor is further configured to: determine the second target opening degree of each of the second flow regulating valves according to the target adsorption mode of the blood purification device; The controller is also used to adjust the opening degree of each of the second flow regulating valves determined by the processor to the corresponding second target opening degree.

8. The blood purification system according to claim 7, characterized in that, A second flow regulating valve is installed between any two adjacent first branch pipes.

9. The blood purification system according to claim 5, characterized in that, The puncture and blood-drawing device includes a puncture needle and an artificial blood vessel. The artificial blood vessel connects the puncture needle and the first tubing. The puncture needle includes a needle body and a needle seat. A needle tip is provided at one end of the needle body away from the needle seat. The needle body is hollow inside. The needle seat connects the needle body and the artificial blood vessel. The inner wall of the artificial blood vessel is coated with an anticoagulant coating.

10. The blood purification system according to claim 5, characterized in that, Also includes: An anticoagulant device includes an injection tubing and a syringe. The input end of the injection tubing is connected to the syringe, which is used to inject an anticoagulant into the injection tubing. The output end of the injection tubing is connected to a first tubing, and the inner wall of the injection tubing is coated with an anticoagulant coating.

Images